Major publications in the critical care pharmacotherapy literature: January–December 2016

Horner, Deanna; Altshuler, Diana; Droege, Chris; Feih, Joel; Ferguson, Kevin; Fiorenza, Mallory; Greathouse, Kasey; Hamilton, Leslie A.; Pfaff, Caitlin; Roller, Lauren K.; Stollings, Joanna L.; Wong, Adrian

doi:10.1016/j.jcrc.2017.09.178

Cited by 8 publications

(6 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Where available, our proposals took information from meta‐analyses of clinical trials, relevant (pharmacological) studies, drug manufacturers, and regulatory agencies into account. Table S7 grades the quality of evidence for proposed LED conversion formulae according to the modified GRADE system 62‐64 . The consensus proposals incorporate the results of the standardized consensus process in which an agreement on a recommendation for the proposals of LED conversion formulae was established for all drugs (Table 2 and Supplementary Material page 1).…”

Section: Resultsmentioning

confidence: 99%

“…Table S7 grades the quality of evidence for proposed LED conversion formulae according to the modified GRADE system. [62][63][64] The consensus proposals incorporate the results of the standardized consensus process in which an agreement on a recommendation for the proposals of LED conversion formulae was established for all drugs (Table 2 and Supplementary Material page 1). Recommendation rates for these proposals ranged between 77.8% (safinamide and zonisamide) and 100% (dual-release and extended-release levodopa, and opicapone) and recommendation rates against these proposals were 11.1% (safinamide and istradefylline) or lower.…”

Section: 7mentioning

confidence: 99%

See 1 more Smart Citation

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: 7mentioning

confidence: 99%

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In addition, recent studies have shown that dexmedetomidine can significantly shorten the time of mechanical ventilation in patients with hyperactive brain syndrome in the ICU compared with haloperidol (12). At present, research reports on the prevention of hyperactive brain syndrome are not rare, but there is still great controversy in the treatment of hyperactive brain syndrome, and there is no in-depth and accurate research to further clarify the comparison of the efficacy of dexmedetomidine (a new sedative) and haloperidol (a traditional antipsychotic) in the treatment of hyperactive brain syndrome in ICU patients (13).…”

Section: Introductionmentioning

confidence: 99%

A systematic review and meta-analysis of the clinical efficacy of the intravenous injection of dexmedetomidine in ICU patients with hyperactive brain syndrome

Wu¹,

Li²,

Ma³

et al. 2022

Ann Palliat Med

View full text Add to dashboard Cite

Background: The incidence of hyperactive brain syndrome in patients in the intensive care unit (ICU) is very high. Compared with other sedative drugs, existing research shows that dexmedetomidine can significantly reduce the incidence of hyperactive brain syndrome. This study systematically analyzed the clinical efficacy of a dexmedetomidine intravenous injection in ICU patients with hyperactive brain syndrome.Methods: The databases PubMed, Web of Science, Embase, and the Cochrane Library were searched from January 2000 to December 2020 to identify papers that studied the clinical efficacy of dexmedetomidine intravenous injection in ICU patients with hyperactive brain syndrome. The basic information and evaluation indexes in the literature were screened and extracted. Revman5.3 software was used for quality assessment and meta-analysis of the included studies, and forest maps were drawn.Results: A total of 255 patients were included in 5 studies. The results of the meta-analysis showed that intravenous infusion of dexmedetomidine could reduce the incidence of restless delirium in patients [odds ratio (OR) =0.14; 95% confidence interval (CI): 0.07 to 0.29; (Z test) Z=5.39, P<0.00001], total delirium after medication duration [mean difference (MD) =−15.50; 95% CI: −25.70 to −5.29; Z=2.98; P=0.003], and ICU hospitalization time (MD =−1.93; 95% CI: −3.57 to −0.29; Z=2.31; P=0.02). However, there was no significant difference in the incidence of adverse reactions (bradycardia and hypotension) in patients who were given an intravenous infusion of dexmedetomidine (OR =2.85; 95% CI: 0.21 to 38.74; Z=0.79; P=0.43).Discussion: The incidence of restlessness delirium, the duration of total delirium after medication, and the length of ICU stay in patients treated with a dexmedetomidine intravenous injection were significantly lower than those in patients treated with haloperidol, indicating that a dexmedetomidine intravenous injection had clinical efficacy in ICU patients with hyperactive brain syndrome.

show abstract

“…To mitigate information overload, strategies have been used to keep up with literature including journal surveillance, interaction with scientific and media communities, and services to journals including article review and editorial work (3). The Clinical Pharmacy and Pharmacology Literature Update (CPPLU) working group within the Society of Critical Care Medicine reviews major critical care journals, distributes a monthly summary to various sections of the Society, and reviews influential articles relevant to critical care pharmacotherapy annually (4)(5)(6)(7)(8)(9)(10)(11)(12)(13). Therefore, we aimed to summarize the most influential publications related to the pharmacotherapeutic care of critically ill patients in 2022.…”

mentioning

confidence: 99%

Major Publications in the Critical Care Pharmacotherapy Literature: 2022

Gurnani,

Barlow,

Boling

et al. 2023

Critical Care Explorations

View full text Add to dashboard Cite

OBJECTIVES: A number of trials related to critical care pharmacotherapy were published in 2022. We aimed to summarize the most influential publications related to the pharmacotherapeutic care of critically ill patients in 2022. DATA SOURCES: PubMed/Medical Literature Analysis and Retrieval System Online and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update. STUDY SELECTION: Randomized controlled trials, prospective studies, or systematic review/meta-analyses of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2022, and December 31, 2022, were included in this article. DATA EXTRACTION: Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included and stratified into clinical domains based upon consistent themes. Consensus was obtained on the most influential publication within each clinical domain utilizing an a priori defined three-round modified Delphi process with the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature. DATA SYNTHESIS: The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update yielded a total of 704 articles, of which 660 were excluded. The remaining 44 articles were stratified into the following clinical domains: emergency/neurology, cardiovascular, gastroenterology/fluids/nutrition, hematology, infectious diseases/immunomodulation, and endocrine/metabolic. The final article selected from each clinical domain was summarized following a three-round modified Delphi process and included three randomized controlled trials and three systematic review/meta-analyses. Article topics summarized included dexmedetomidine versus other sedatives during mechanical ventilation, beta-blocker treatment in the critically ill, restriction of IV fluids in septic shock, venous thromboembolism prophylaxis in critically ill adults, duration of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia, and low-dose methylprednisolone treatment in severe community-acquired pneumonia. CONCLUSIONS: This concise review provides a perspective on articles published in 2022 that are relevant to the pharmacotherapeutic care of critically ill patients and their potential impact on clinical practice.

show abstract

Major publications in the critical care pharmacotherapy literature: January–December 2016

Cited by 8 publications

References 132 publications

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

A systematic review and meta-analysis of the clinical efficacy of the intravenous injection of dexmedetomidine in ICU patients with hyperactive brain syndrome

Major Publications in the Critical Care Pharmacotherapy Literature: 2022

Contact Info

Product

Resources

About